Track THP-1 Monocyte Signal Transduction with a Bigger, Better, Brighter Signal Webinar
November 10, 2022, at 12:00 PM ETAbstract
Cancer immunotherapy has emerged as an exciting new approach for cancer treatment, and immuno-oncology is one of the fastest growing fields in oncology. The development of immunomodulatory drugs and biologics dictates a clear demand for human cell-based models to evaluate immune activation. To address this need, ATCC generated THP-1 luciferase reporter cell lines that contain the response elements of immune-regulated transcription factors such as NF-κB, GAS, CRE, and AP-1. With high sensitivity and specificity, these cell lines produce an intense, dose-dependent luciferase signal upon stimulation. This webinar will present data showing that THP-1 luciferase reporter cell lines are valuable tools for studying signal transduction pathways, screening of compounds to find activators or inhibitors of immune response, and evaluating the efficacy of new drugs and chemicals. Be sure to stick around for a lively, live Q and A session with our RnD experts.
Key Points
- THP-1 cell line is a commonly used surrogate model for in vitro human primary monocytes
- Luciferase reporter system provides a straightforward, robust, and sensitive means to measure biological processes through in vitro bioluminescence measurements
- THP-1 luciferase reporter cell lines allow broad application in drug development, cell signaling pathway research, and as a safety evaluation tool for new chemicals and drugs
Presenters
Brian Della Fera, BS
Biologist, ATCC
Brian is a Biologist at ATCC in the Translational Cell Biology division. He has extensive experience in the fields of molecular biology and immunology. His current role is creating cell lines and tools for broad applications in immuno-oncology. Brian holds a bachelor’s degree in Molecular Biology from West Chester University of Pennsylvania.
Fang Tian, PhD
Director, Biological Content, ATCC
Dr. Fang Tian, Director of Biological Content for ATCC, has extensive experience in cell biology and molecular biology. She oversees human, animal cell lines and hybridomas, and product development in the Cell Biology General Collection at ATCC. Dr. Tian was a research fellow in Massachusetts General Hospital, Harvard Medical School. She conducted postdoctoral research at the Hillman Cancer Institute of UPMC.
